Abstract: There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.

Abstract: The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e.g., adoptive cell therapy).

Abstract: There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.

Abstract: The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy.

Abstract: The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy.

Abstract: The present application presents peptides that binds selectively to fungi, in particular opportunistic fungi, and not to human cells. These properties can be utilized to specifically target invading fungal pathogens, and via genetic engineering create peptibodies. Thus, the present application describes novel approaches for detection and treatment of infections caused by fungi.

Abstract: A three dimensional ultrasound imaging device is provided. The three dimensional ultrasound imaging device comprises a processing unit and an interface. The processing unit is configured to obtain from an ultrasound scanning machine, via the interface, scanning data indicative of a tissue sample and a reference element. The processing unit is configured to obtain, based on the scanning data, image data, where the image data is indicative of the tissue sample and the reference element. The processing unit is configured to determine, based on the image data, a tissue sample representation.

Abstract: An image information processing apparatus according to an embodiment includes processing circuitry. The processing circuitry acquires a structure from a medical image, sets one or more lines or planes that divide the structure into a plurality of regions, calculates feature quantities related to a form of the structure for each of the regions, and corrects the structure so that a difference in the feature quantities is reduced.

Abstract: An image information processing apparatus provided in one aspect of the present invention includes processing circuitry. The processing circuitry acquires the same structure from a plurality of medical images captured at different times or by different devices, calculates feature quantities related to the form of the structure for each of the medical images, and corrects the structure so that a difference in the feature quantities is reduced.

Abstract: Novel 18F-labelled tetrazines are provided which are highly reactive to be effective in vivo, suitable for pretargeted positron emission tomography (PET) and accessible in radiochemical yields (RCYs) which allow access to 18F-labeled tetrazines for clinical applications. The 18F-labelled tetrazines are developed using a Cu-mediated click indirect labelling approach. Only a subset of compounds appeared to be suitable for clinical pretargeted imaging strategies, and a particular compound which includes the use of an 18F-labelled azide synthon having an azide structure with glucose as the linker and a triazole moiety within the linker, appears to be highly suited for clinical pretargeted imaging purposes.

Abstract: A medical image processing apparatus according to an embodiment includes processing circuitry. The processing circuitry is configured to obtain a medical image related to the heart. The processing circuitry is configured to generate a polar map indicating myocardial function information on the basis of the medical image. The processing circuitry is configured to cause a display to display a blood vessel image indicating forms of blood vessels included in the heart so as to be superimposed on the polar map. The processing circuitry is configured to receive an operation to designate at least one of the blood vessels displayed over the polar map. The processing circuitry is configured to identify information associated with the blood vessel designated by the operation. The processing circuitry is configured to cause the display to display the information associated with the blood vessel.

Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.

Abstract: The present invention relates to tumor-targeted probes for use as medicaments and for use in treatment of cancer and to methods of treatment wherein such probes are used. The probes consist of a light-absorbing molecule linked directly or via a spacer to a peptide targeting the urokinase-type plasminogen activator receptor (uPAR). When irradiating the light-absorbing molecule of the probe with laser beams from an external source heat will be released locally to tumor cells expressing uPAR resulting in tumor ablation.

Abstract: The present disclosure relates to a system for generating a predefined electrical signal in an MR scanner for use in electrical stimulation of a subject during MRI or functional MRI of said subject, wherein said MR scanner is located inside a shielded MRI room. The system comprises a control unit to be located outside the MRI room for generating an electrical signal and an electrical to optical converter to be located outside the MRI room for converting said electrical signal to a corresponding optical signal. An optical transmitting element, such as an optical fiber, is used for transmitting the optical signal into the MRI room, and an optical to electrical converter is used for converting the optical signal to said predefined electrical signal for electrical stimulation of the subject during magnetic resonance imaging. The optical to electrical converter is configured for being located inside the MRI room and for operation during magnetic resonance imaging.

Abstract: The present invention relates to novel tetrazine compounds of formula I, wherein one of R1-R5 is 18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The invention further relates to precursors to formula I, wherein one of R1-R5 is SnR3, B(OR)2, B(0H)2. Formula (I).

Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.

Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.

Abstract: The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy.

Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.